Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Summary of Significant Accounting Policies - Revenue from contract with customers (Details)

v3.10.0.1

Summary of Significant Accounting Policies - Revenue from contract with customers (Details) £ in Millions	1 Months Ended				3 Months Ended		9 Months Ended		13 Months Ended	53 Months Ended
	Sep. 30, 2018 USD ($)	Sep. 30, 2017 GBP (£)	Sep. 30, 2017 USD ($)	Jun. 30, 2014 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($) Milestone contract	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2018 USD ($)
Collaboration and License Agreement
Revenue					$ 40,792,000	$ 27,185,000	$ 58,026,000	$ 33,563,000
PRAME program
Collaboration and License Agreement
Number of small-dollar development milestone \| Milestone							1
GlaxoSmithKline Intellectual Property Development Ltd \| Collaboration and License Agreement
Collaboration and License Agreement
Number of contracts with customers \| contract							1
Option Exercise Fee, received		£ 20	$ 26,600,000
Upfront payment received				$ 42,123,000
Amount of development milestone achieved										$ 66,404,000
Estimate of variable consideration							$ 0
License revenue
Collaboration and License Agreement
Revenue					$ 39,114,000		$ 39,114,000
License revenue \| GlaxoSmithKline Intellectual Property Development Ltd \| Collaboration and License Agreement
Collaboration and License Agreement
Revenue	$ 13,175,000		$ 26,610,000						$ 39,785,000

- Definition

Represents cash received upon achievement of development milestones.

+ References

No definition available.

+ Details

Name:	adap_LicenseAgreementAchievementOfDevelopmentMilestones
Namespace Prefix:	adap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the variable consideration entitled upon achievement of development milestones.

+ References

No definition available.

+ Details

Name:	adap_LicenseAgreementVariableConsideration
Namespace Prefix:	adap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of first tranche of the option exercise fee receivable for exercising of agreement.

+ References

No definition available.

+ Details

Name:	adap_LicenseExerciseFeeReceivable
Namespace Prefix:	adap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the total number of contracts with customers.

+ References

No definition available.

+ Details

Name:	adap_NumberOfContractsWithCustomer
Namespace Prefix:	adap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of small-dollar development milestone the Company may be entitled for pre-clinical development.

+ References

No definition available.

+ Details

Name:	adap_NumberOfSmallDollarDevelopmentMilestoneEntitlement
Namespace Prefix:	adap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Cash received from licensees for license fees during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=adap_CollaborativeArrangementPerformanceObligationsForPRMEProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=adap_GlaxosmithklineIntellectualPropertyDevelopmentLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: